How to implement recent guidelines into clinical practice of CTD/SARD-ILDs

Synopsis:

Interstitial lung disease (ILD) is characterized by inflammation and/or fibrosis of the lung parenchyma and is a leading cause of morbidity and mortality in people with connective tissue diseases (CTDs) or systemic autoimmune rheumatic diseases (SARDs). CTD/SARD patients are at risk for developing ILD in general, while patients with rheumatoid arthritis, systemic sclerosis, idiopathic inflammatory myopathies, mixed connective tissue disease, and Sjögren disease are at particularly high risk. In recent years, evidence has been accumulating regarding screening, risk factors for progression and/or poor outcome, monitoring, and treatment of CTD/SARD-ILD. Under these circumstances, guidelines for management of CTD/SARD-ILD have been developed by various academic societies. These guidelines refer to the same evidence, but their interpretations are not necessarily the same. Therefore, it can be difficult to determine how to incorporate these guidelines into clinical practice. This seminar will provide useful information for daily clinical practice through a brief summary by experts of the ACR/CHEST, EULAR/ERS, and JRS/JCR guidelines and a panel discussion.